Posts for category: Recent News

AgeneBio’s Phase 2B Trial Shows AGB101 Slows Progression of Brain Atrophy in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease Who Are Non-Carriers of the APoE-4 Allele

• The Phase 2B trial showed 40% less clinical decline and significantly reduced atrophy of the entorhinal cortex, a key marker of disease progression, compared to placebo in ApoE-4 non- carriers with MCI due to AD • Patients were given a once-daily dose of AGB-101, a proprietary low-dose extended-release formulation of levetiracetam or placebo in…

AgeneBio leadership presents at American Society for Experimental Neurotherapeutics Annual Meeting

AGB101 for the treatment of neuropsychiatric symptoms in Parkinson’s disease Presenter: Arnold Bakker, Ph.D., Johns Hopkins University Abstract Authors: Arnold Bakker, Gregory Pontone, Richard Mohs, Michela Gallagher Poster Presentation Hippocampal hyperactivity is a pathological hallmark of Alzheimer’s disease (AD) and a prognostic indicator of AD progression and clinical cognitive worsening in amnestic mild cognitive impairment…

Boosting the Brain’s Brakes to Beat Memory Loss

Overactivity in the hippocampus, likely tied to lack of inhibition, underlies some age-related cognitive decline. Targeting those circuits shows early promise in slowing memory loss. Read More: “Boosting the Brain’s Brakes to Beat Memory Loss”

AgeneBio Announces Completion of Patient Enrollment in Phase 2B Clinical Trial to Evaluate AGB101 to Treat Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease

– Topline results expected in November 2022 BALTIMORE, April 21, 2021 — AgeneBio announced today that it has completed enrollment in a Phase 2B clinical trial evaluating the efficacy of AGB101, a once-a-day investigational medication to treat amnestic Mild Cognitive Impairment due to Alzheimer’s Disease (MCI due to AD). The clinical trial, known as “HOPE4MCI” (NCT03486938), is a 78-week…